<p><h1>Fragment-based Drug Discovery Market Research Report Reveals The Latest Trends And Opportunities of this Market for Period from 2023 - 2030</h1></p><p><strong>Fragment-based Drug Discovery Market Analysis and Latest Trends</strong></p>
<p><p>Fragment-based drug discovery (FBDD) is a powerful approach used in the early stages of drug development. It involves the identification and optimization of small chemical fragments that bind to a biological target of interest, leading to the development of potent and selective drug candidates. FBDD is based on the principle that small, low-affinity fragments can be linked together or elaborated to create high-affinity drug-like compounds.</p><p>The fragment-based drug discovery market is expected to witness significant growth in the coming years. Factors driving this growth include the increasing prevalence of chronic diseases, such as cancer and neurological disorders, which require innovative treatment options. FBDD offers advantages over traditional methods, such as higher success rates and reduced time and cost. This has led to increased adoption of FBDD by pharmaceutical and biotechnology companies.</p><p>Additionally, advancements in technologies, such as high-throughput screening and nuclear magnetic resonance (NMR) spectroscopy, have facilitated the implementation of FBDD. These technologies allow for the rapid screening and characterization of large fragment libraries, enabling the identification of potential drug candidates.</p><p>Moreover, the increasing emphasis on personalized medicine and the demand for targeted therapies further contribute to the growth of the FBDD market. FBDD allows for the design of compounds that specifically target the underlying molecular mechanisms of a particular disease, leading to improved efficacy and reduced side effects.</p><p>The COVID-19 pandemic has also had a significant impact on the FBDD market. The urgent need for effective antiviral drugs has driven research and development activities in the field of fragment-based drug discovery. Several companies and academic institutions are actively exploring FBDD as a potential approach for discovering antiviral drugs against novel coronaviruses.</p><p>Overall, the fragment-based drug discovery market is expected to experience steady growth, driven by technological advancements, increasing prevalence of chronic diseases, and the need for more effective and targeted therapies. The market is projected to grow at a CAGR of 12.4% during the forecast period.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp; <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1506769">https://www.reliableresearchreports.com/enquiry/request-sample/1506769</a></strong></p>
<p>&nbsp;</p>
<p><strong>Fragment-based Drug Discovery Major Market Players</strong></p>
<p><p>The fragment-based drug discovery (FBDD) market is highly competitive, with several key players operating in the industry. Some prominent companies in this market include Astex Pharmaceuticals, Alveus Pharmaceuticals, Beactica, Charles River Laboratories, Crown Bioscience, Emerald BioStructures, Evotec, Kinetic Discovery, Proteros Fragments, Sprint Bioscience, Structure Based Design, and Sygnature Discovery.</p><p>Astex Pharmaceuticals is a leading player in the FBDD market, offering a range of innovative fragment-based screening technologies. The company was founded in 1999 and has since experienced significant growth. It has established a strong presence in the market through strategic partnerships and collaborations with pharmaceutical giants like AstraZeneca and Novartis. Astex Pharmaceuticals recorded revenues of approximately $250 million in 2020, indicating its substantial market size and growth.</p><p>Evotec is another key player that provides fragment-based drug discovery services. It was founded in 1993 and has evolved into a leading drug discovery and development company. Evotec offers a comprehensive suite of FBDD capabilities, including target identification, hit identification, and lead optimization. The company has witnessed steady market growth over the years due to its expertise in fragment-based approaches. Evotec reported revenues of around $560 million in 2020, demonstrating its market size and significant sales revenue.</p><p>Charles River Laboratories is a globally renowned drug discovery and development services company. While not solely focused on FBDD, the company offers a range of services, including fragment-based drug discovery. Charles River Laboratories has a strong reputation in the industry and serves clients from various sectors, including pharmaceuticals, biotechnology, and academia. With a diverse portfolio of services, the company has achieved substantial market growth. In 2020, Charles River Laboratories generated revenues of approximately $2.86 billion, solidifying its position as a key player in the market.</p><p>These examples provide an overview of some prominent companies in the FBDD market, highlighting their past history, market growth, market size, and sales revenue. It is important to note that the market is dynamic, with companies constantly evolving and introducing new technologies and services. Therefore, continuous monitoring of the competitive landscape is necessary to stay updated with the latest developments in the field.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Fragment-based Drug Discovery Manufacturers?</strong></p>
<p><p>The fragment-based drug discovery market is witnessing significant growth and is expected to continue its upward trajectory in the coming years. This growth can be attributed to several factors, including the rising focus on improving the efficiency and success rate of drug discovery processes. Fragment-based drug discovery offers several advantages, such as the ability to identify potential drug candidates with lower molecular weight and reduced complexity. Additionally, advancements in technology and increased investments in research and development activities are further driving the growth of this market. With ongoing developments and increasing adoption, the future outlook of the fragment-based drug discovery market looks promising.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report: <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1506769">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1506769</a></strong></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Fragment-based Drug Discovery Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Fragment Screening</li><li>Fragment Optimization</li></ul></p>
<p><p>Fragment-based drug discovery (FBDD) is a strategy in drug development that involves identifying small chemical fragments that bind to a target protein. These fragments are then optimized to develop potent and selective drug candidates. The FBDD market comprises two main types: fragment screening and fragment optimization. Fragment screening involves the initial identification and screening of fragments against target proteins to determine their binding affinity. Fragment optimization entails improving the selected fragments through chemical modifications and structural optimization to enhance their drug-like properties. Both these approaches play a crucial role in the early stages of drug discovery processes.</p></p>
<p><strong>Purchase this Report:&nbsp;<a href="https://www.reliableresearchreports.com/purchase/1506769">https://www.reliableresearchreports.com/purchase/1506769</a></strong></p>
<p>&nbsp;</p>
<p><strong>The Fragment-based Drug Discovery Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Academic and Research Institutions</li><li>Biopharmaceutical Companies</li><li>Contract Research Organizations (CROs)</li></ul></p>
<p><p>The fragment-based drug discovery market has various applications, such as in academic and research institutions, where it provides valuable tools and methods for studying the structure and function of proteins. Biopharmaceutical companies benefit from fragment-based drug discovery as it offers a more efficient and cost-effective approach to drug development. Contract research organizations (CROs) also play a significant role in this market by providing expertise and services to assist the drug discovery process for academic institutions and biopharmaceutical companies.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Fragment-based Drug Discovery Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The global fragment-based drug discovery market is expected to witness significant growth in the regions of North America (NA), Asia-Pacific (APAC), Europe, USA, and China. This growth can be attributed to increasing drug discovery activities, rising investments in research and development, and advancements in technology. Among these regions, North America is anticipated to dominate the market, primarily due to the presence of major pharmaceutical companies and extensive drug research activities. Currently, North America accounts for the largest market share of approximately 40%, followed by Europe with around 30% market share. Meanwhile, Asia-Pacific, USA, and China are expected to exhibit substantial growth and gradually gain market share in the coming years.</p></p>
<p><strong>Purchase this Report: <a href="https://www.reliableresearchreports.com/purchase/1506769">https://www.reliableresearchreports.com/purchase/1506769</a></strong></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;<a href="https://www.reliableresearchreports.com/enquiry/request-sample/1506769">https://www.reliableresearchreports.com/enquiry/request-sample/1506769</a></strong></p>
<p><strong></strong></p>
<p><p><a href="https://medium.com/@beauhagenes2023/procaine-penicillin-g-market-size-growth-forecast-2023-2030-6755cff96e15">Procaine Penicillin G Market</a></p><p><a href="https://www.linkedin.com/pulse/lightning-rod-towers-market-size-share-global-analysis/">Lightning Rod Towers Market</a></p><p><a href="https://www.linkedin.com/pulse/inorganic-metal-finishing-market-size-share-global-analysis-report/">Inorganic Metal Finishing Market</a></p><p><a href="https://www.linkedin.com/pulse/safety-connection-devices-market-size-share-amp-trends/">Safety Connection Devices Market</a></p><p><a href="https://medium.com/@leliajewess/drotaverine-hydrochloride-market-research-report-its-history-and-forecast-2023-to-2030-04ada3cd44e1">Drotaverine Hydrochloride Market</a></p></p>